TITLE

Kids get new upset-stomach remedy

PUB. DATE
December 2007
SOURCE
Drug Store News;12/10/2007, Vol. 29 Issue 15, p37
SOURCE TYPE
Trade Publication
DOC. TYPE
Product Review
ABSTRACT
The article evaluates the Tums Kids' stomach relief product from the GlaxoSmithKline company.
ACCESSION #
27972436

 

Related Articles

  • POTIGA.  // Monthly Prescribing Reference;Jul2012, Vol. 28 Issue 7, pA5 

    The article offers brief information on Potiga drug from GlaxoSmithKline.

  • Anoro Ellipta.  // MPR - Pharmacist's Edition;Summer2014, Vol. 8 Issue 2, pA8 

    The article offers brief information on the drug Anoro Ellipta from GlaxoSmithKline.

  • GSK ends Serevent study after FDA analysis. Dickinson, James D. // Medical Marketing & Media;Mar2003, Vol. 38 Issue 3, p28 

    Reports on the conclusion of an interim analysis of the asthma drug Serevent from GlaxoSmithKline Inc. in the U.S. Difficulties in enrollment; Absence of significant result on the primary endpoint; Need for doctor's consultation in taking Serevent.

  • Avandia heart safety review.  // Monthly Prescribing Reference;Mar2010, Vol. 26 Issue 3, pA18 

    The article reports on the plans of the U.S. Food and Drug Administration (FDA) to evaluate the cardiovascular safety of Avandia, a rosiglitazone from GlaxoSmithKline.

  • Enrollment Is Halted In Tests of Avandia.  // Chain Drug Review;8/30/2010, Vol. 32 Issue 14, p40 

    The article reports on the cessation of the enrolling new patients in a clinical trial of the antidiabetic drug Avandia from GlaxoSmithKline in the U.S.

  • Early optimism. Goymer, Patrick // Nature Reviews Cancer;May2006, Vol. 6 Issue 5, p342 

    The article reports that GlaxoSmithKline (GSK) has ended its study on the benefits of lapatinib ditosylate, a drug for herceptin-resistant breast cancer, and is proceeding to obtain regulatory approval in the U.S. The drug is a small-molecule dual-kinase inhibitor that targets both...

  • Opinion: GlaxoSmithKline: Tykerb steps up challenge to Herceptin.  // PharmaWatch: Cancer;Jun2008, Vol. 7 Issue 6, p7 

    The author reflects on the Phase III trial comparing Tykerb and Herceptin neoadjuvant therapies by GlaxoSmithKline in Europe. According to the author, the tests would analyze the potentiality of the two newly introduced drugs. The author contends that the Phase III trials would favor Tykerb...

  • Companies 'supressed' negative research into child drugs.  // Ecologist;Jun2004, Vol. 34 Issue 5, p8 

    Reports on the suppression of negative results in child drugs trials by pharmaceutical companies. Contents of leaked memo from pharmaceutical company GlaxoSmithKline proving the allegations of data suppression; Percentage of negative reports on cancer drug trials based on a review of previous...

  • Malaria vaccine enters phase III clinical trials.  // Nature;6/4/2009, Vol. 459 Issue 7247, p627 

    The article reports that the pre-approval testing of the RTS,S malaria vaccine from GlaxoSmithKline has entered its phase III trials on May 26, 2009 in Bagamoyo, Tanzania. It states that the study will become the largest clinical trial for malaria vaccine, in which it involves 16,000 children...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics